Eisai Files Alzheimer’s Drug Lecanemab In Europe But Will EMA Grant Fast Track?

Accelerated Assessment Could Cut Months Off Review

 
• By Andrew McConaghie
  
EMA
EMA grants accelerated assessment to medicines of potential major public health interest • Source: Getty Images

More from Approvals

More from Product Reviews